<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurochem Res</journal-id><journal-id journal-id-type="iso-abbrev">Neurochem Res</journal-id><journal-title-group><journal-title>Neurochemical Research</journal-title></journal-title-group><issn pub-type="ppub">0364-3190</issn><issn pub-type="epub">1573-6903</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39562371</article-id><article-id pub-id-type="pmc">PMC11576791</article-id>
<article-id pub-id-type="publisher-id">4263</article-id><article-id pub-id-type="doi">10.1007/s11064-024-04263-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Differential Effects of Itaconate and its Esters on the Glutathione and Glucose Metabolism of Cultured Primary Rat Astrocytes</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2811-8118</contrib-id><name><surname>Watermann</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-1924-1635</contrib-id><name><surname>Kalsi</surname><given-names>Gurleen K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7869-1305</contrib-id><name><surname>Dringen</surname><given-names>Ralf</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8690-6257</contrib-id><name><surname>Arend</surname><given-names>Christian</given-names></name><address><email>christian.arend@uni-bremen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ers2y35</institution-id><institution-id institution-id-type="GRID">grid.7704.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 4381</institution-id><institution>Centre for Biomolecular Interactions Bremen, Faculty 2 (Biology/Chemistry), </institution><institution>University of Bremen, </institution></institution-wrap>28359 Bremen, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ers2y35</institution-id><institution-id institution-id-type="GRID">grid.7704.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 4381</institution-id><institution>Centre for Environmental Research and Sustainable Technology, </institution><institution>University of Bremen, </institution></institution-wrap>28359 Bremen, Germany </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>50</volume><issue>1</issue><elocation-id>24</elocation-id><history><date date-type="received"><day>7</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>9</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>7</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Itaconate is produced as endogenous metabolite by decarboxylation of the citric acid cycle intermediate <italic>cis</italic>-aconitate. As itaconate has anti-microbial and anti-inflammatory properties, this substance is considered as potential therapeutic drug for the treatment of inflammation in various diseases including traumatic brain injury and stroke. To test for potential adverse effects of itaconate on the viability and metabolism of brain cells, we investigated whether itaconate or its membrane permeable derivatives dimethyl itaconate (DI) and 4-octyl itaconate (OI) may affect the basal glucose and glutathione (GSH) metabolism of cultured primary astrocytes. Acute exposure of astrocytes to itaconate, DI or OI in concentrations of up to 300 &#x000b5;M for up to 6&#x000a0;h did not compromise cell viability. Of the tested substances, only OI stimulated aerobic glycolysis as shown by a time- and concentration-dependent increase in glucose-consumption and lactate release. None of the tested itaconates affected the pentose-phosphate pathway-dependent reduction of the water-soluble tetrazolium salt 1 (WST1). In contrast, both DI and OI, but not itaconate, depleted cellular GSH in a time- and concentration-dependent manner. For OI this depletion was accompanied by a matching increase in the extracellular GSH content that was completely prevented in the presence of the multidrug resistance protein 1 (Mrp1)-inhibitor MK571, while in DI-treated cultures GSH was depleted both in cells and medium. These data suggest that OI stimulates Mrp1-mediated astrocytic GSH export, while DI reacts with GSH to a conjugate that is not detectable by the GSH assay applied. The data presented demonstrate that itaconate, DI and OI differ strongly in their effects on the GSH and glucose metabolism of cultured astrocytes. Such results should be considered in the context of the discussed potential use of such compounds as therapeutic agents.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Astrocytes</kwd><kwd>Glutathione</kwd><kwd>Glycolysis</kwd><kwd>Itaconate</kwd><kwd>Pentose-phosphate pathway</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e4;t Bremen (1013)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Itaconic acid (2-methylidenebutanedioic acid) is a mammalian metabolite that is produced in stimulated macrophages [<xref ref-type="bibr" rid="CR1">1</xref>]. The enzyme <italic>cis</italic>-aconitate decarboxylase generates itaconate by decarboxylation of the citric acid cycle intermediate <italic>cis</italic>-aconitate, thereby linking in macrophages mitochondrial metabolism to immunity [<xref ref-type="bibr" rid="CR2">2</xref>]. Itaconate is a dicarboxylic acid that contains five carbon atoms and an &#x003b1;,&#x003b2;-unsaturated alkene structure. Due to its two negatively charged carboxylate groups, itaconate applied to cells is considered to possess low membrane permeability. To overcome this problem, itaconate esters with higher lipophilicity and membrane permeability such as dimethyl itaconate (DI, dimethyl 2-methylidenebutanedioate) or 4-octyl itaconate (OI, 2-methylidene-4-octoxy-4-oxobutanoic acid) are frequently used to study pharmacological effects of itaconate in vivo and in vitro [<xref ref-type="bibr" rid="CR3">3</xref>]. The finding that itaconate can activate the Nrf2 signaling pathways by alkylation of Keap1, thereby initiating the transcription of pro-inflammatory and anti-oxidant genes, has made itaconate a promising candidate for therapeutic applications in a variety of diseases and tissue types [<xref ref-type="bibr" rid="CR4">4</xref>]. In the context of the brain, itaconate is currently considered for treatments of traumatic brain injury, stroke and neuroinflammation-associated depression [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Moreover, itaconate has very recently been shown to be secreted from activated macrophages and activates an innate immune response signaling pathway in the respiratory epithelium by activation of oxoglutarate receptor 1 (OXGR1) [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par3">The brain consists mainly of neurons and glial cells, whereby astrocytes represent the majority of glial cells [<xref ref-type="bibr" rid="CR7">7</xref>]. These cells hold a pivotal role in the brain&#x02019;s normal and drug-related metabolism [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. As astrocytes are deeply involved and differentially activated in several neurological disorders including ischemic stroke, traumatic brain injury and Alzheimer&#x02019;s disease, they are considered as promising therapeutic target [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Moreover, astrocytic end-feet cover the brain capillaries nearly completely and, as a consequence, astrocytes are the first parenchymal brain cell type that encounters substances delivered by the bloodstream and cross the blood-brain barrier [<xref ref-type="bibr" rid="CR16">16</xref>]. Importantly, astrocytes are also tightly associated with neuronal synapses [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and take up extracellular neurotransmitters from the synaptic cleft thereby maintaining synaptic connectivity [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, astrocytes supply neurons with precursors for glutathione (GSH) synthesis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par4">The tripeptide GSH (&#x003b3;-glutamyl-cysteinyl-glycine) is an important antioxidant that is present in the cytosol of cultured astrocytes in a concentration of 8 mM [<xref ref-type="bibr" rid="CR21">21</xref>]. GSH is oxidized to glutathione disulfide (GSSG) during oxidative stress [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. This oxidation provides electrons that are used for the reduction of reactive oxygen species (ROS) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The accumulating GSSG is rapidly reduced to GSH by the NADPH-dependent glutathione reductase [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] or, if GSSG reduction is limited, can be exported from cultured astrocytes to slow-down the rapid oxidation of the cellular thiol reduction potential [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Astrocytes do also export GSH as first step of the supply of precursor molecules for GSH synthesis in neighbouring neurons [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Furthermore, GSH is a key player in the cellular detoxification of organic compounds, since it can be conjugated to various types of xenobiotics via glutathione-<italic>S</italic>-transferases. This helps to detoxify potentially harmful substances, which are subsequently exported from the cells via multidrug-resistance proteins [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. The multidrug-resistance protein 1 (Mrp1) is, together with other ABC-family members, expressed in primary astrocyte cultures [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and has been demonstrated to mediate the export of GSH [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] and GSSG from these cells [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The export of these two Mrp1 substrates from astrocyte cultures has been reported to be efficiently inhibited by the Mrp1 inhibitor MK571 [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par5">So far little information is available on the consequences of an exposure of astrocytes to itaconate. Application of itaconate in a high concentration of 2 mM promotes succinate accumulation by reversible inhibition of succinate dehydrogenase activity in vitro in primary astrocyte cultures [<xref ref-type="bibr" rid="CR35">35</xref>]. For these conditions, an increase in the intracellular amounts of itaconate to around 3 nmol/well was detected, suggesting that itaconate is able to enter astrocytes, at least if applied in millimolar concentrations [<xref ref-type="bibr" rid="CR35">35</xref>]. Very recently, OI was reported to enhance the expression of Nrf2 and its nuclear translocation in astrocytes in an in vivo mouse hypoxic ischemic model [<xref ref-type="bibr" rid="CR36">36</xref>]. Also after incubation of primary astrocytes with DI, activation of Nrf2 was reported in addition to increased activities of the antioxidative enzymes catalase and superoxide dismutase and an elevated GSH/GSSG ratio [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par6">In order to investigate whether an acute exposure with itaconate or its derivatives DI or OI may affect the GSH or glucose metabolism of brain cells, cultured primary astrocyte cultures were incubated in the absence or presence of either of these three compounds and the cellular and extracellular amounts of GSH and GSSG, the glucose consumption, the lactate release and the ability to provide electrons via the pentose phosphate pathway (PPP) for WST1 reduction were investigated. Here we report that under the conditions applied, the presence of itaconate had no modulatory effect on the investigated metabolic parameters. In contrast, DI strongly reduced the amounts of detectable cellular and extracellular GSH, most likely by conjugation via a Michael-type reaction, while OI stimulated the Mrp1-mediated export of GSH and the glycolytic lactate production.</p></sec><sec id="Sec2"><title>Experimental Procedures</title><sec id="Sec3" sec-type="materials|methods"><title>Materials and Methods</title><p id="Par7">Itaconic acid (I29204), dimethyl itaconate (DI; 592498) and fetal calf serum (F7524) were purchased from Sigma-Aldrich (Steinheim, Germany, RRID: SCR_008988). 4-Octyl itaconate (OI; 25374) and G6PDi-1 (31484) were from Cayman Chemical (Tallinn, Estonia; RRID: SCR_008945). MK-571 (MK571; AG-CR1-0021) was purchased form AdipoGen Life Sciences (San Diego, USA; RRID: SCR_010507). WST1 (W201) was from Dojindo (Munich, Germany) and &#x003b2;-lapachone (ab141097) from Abcam (Berlin, Germany; RRID: SCR_012931). Acivicin (sc-200498) was bought from Santa Cruz Biotechnology (Heidelberg, Germany; RRID: SCR_008987). Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM containing 25 mM glucose; 12100061) and penicillin G/streptomycin sulfate solution (15140122) was obtained from Thermo Fisher Scientific (Schwerte, Germany; RRID: SCR_008452). Sulfosalicylic acid (SSA; A0416), bovine serum albumin (BSA; A1391), NADPH (A1395) and NADH (A1393) were purchased from Applichem (Darmstadt, Germany; RRID: SRC_005814). The enzyme glutathione reductase (G3664) was from Sigma-Aldrich (Steinheim, Germany, RRID: SCR_008988). The enzymes glucose-6-phosphate dehydrogenase (10165875001), hexokinase (11426362001), glutamate-pyruvate transaminase (10737127001) and lactate dehydrogenase (10127876001) were obtained from Roche Diagnostics (Mannheim, Germany; RRID: SCR_001326). All other chemicals of the highest purity available were obtained from Merck (Darmstadt, Germany; RRID: SCR_001287), Sigma-Aldrich (Steinheim, Germany; RRID: SCR_008988), Fluka (Buchs, Switzerland), Roth (Karlsruhe, Germany; RRID: SCR_005711) or Riedel-de-Ha&#x000eb;n (Seelze, Germany). Sterile cell culture plates and unsterile 96-well microtiter plates were from Sarstedt (N&#x000fc;mbrecht, Germany).</p></sec><sec id="Sec4"><title>Astrocyte Cultures</title><p id="Par8">Brains of newborn Wistar rats were used to prepare astrocyte-rich primary cultures as previously described in detail [<xref ref-type="bibr" rid="CR38">38</xref>]. Briefly, after mechanical dissociation of brain tissue, the suspension of harvested cells was diluted in culture medium (90% DMEM containing 25 mM glucose, 20 U/mL penicillin G, 20&#x000a0;&#x000b5;g/mL streptomycin, 44.6 mM NaHCO<sub>3</sub> and 1 mM pyruvate supplemented with 10% fetal calf serum) and 300 000 viable cells in 1 mL medium were seeded into wells of 24-well plates. The cultures were incubated at 37&#x000a0;&#x000b0;C in a humidified atmosphere in a Sanyo incubator (Osaka, Japan) supplying 10% CO<sub>2</sub>. The culture medium was renewed every 7th day and 24&#x000a0;h prior to each experiment. All experiments for the presented study were performed on confluent cultures of an age between 17 and 27 days. Most cells in these cultures are astrocytes and only low amounts of contaminating oligodendrocytes and microglial cells are present [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec5"><title>Experimental Incubation of the Cells</title><p id="Par9">The cells were washed twice with 1 mL prewarmed (37&#x000a0;&#x000b0;C) incubation buffer (IB; 20 mM HEPES, 5 mM D-glucose, 145 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 0.8 mM Na<sub>2</sub>HPO<sub>4</sub>, pH adjusted with NaOH at 37&#x000a0;&#x000b0;C to 7.4) and incubated at 37&#x000a0;&#x000b0;C with 200 &#x000b5;L IB containing 100 &#x000b5;M of the &#x003b3;-glutamyltranspeptidase inhibitor acivicin [<xref ref-type="bibr" rid="CR40">40</xref>] in the absence or the presence of the compounds indicated in the figures and tables. After the given incubation periods, the media were collected for determination of extracellular levels of GSx, GSSG, glucose and lactate as well as extracellular LDH activity. The cells were washed with 1 mL of ice-cold phosphate-buffered saline (PBS; 10 mM potassium phosphate buffer, pH 7.4, containing 150 mM NaCl) before the extracellular and cellular contents of GSx (GSx&#x02009;=&#x02009;amount of GSH plus twice the amount of GSSG) and GSSG were determined.</p></sec><sec id="Sec6"><title>Cell-free Incubation of GSH with Itaconate and its Derivatives</title><p id="Par10">GSH (10 &#x000b5;M) was incubated without (0 &#x000b5;M) or with 1 mM or 10 mM itaconate, DI or OI for up to 4&#x000a0;h in 1 mL IB in wells of a 24-well dish at room temperature. Afterwards, the GSH content was determined as described below.</p></sec><sec id="Sec7"><title>Determination of Cell Viability and Cellular Protein Content</title><p id="Par11">Lactate dehydrogenase (LDH) is a cytosolic enzyme that is released from cells upon impairment of membrane integrity. Hence, extracellular LDH activity has been monitored as indication for a potential loss in cell viability as previously described in detail [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. To calculate specific metabolite values, the data for the contents of GSx and GSSG, lactate release, glucose consumption and WST1 formazan formation were normalized to the protein content of the individual cultures, which was measured by the Lowry method [<xref ref-type="bibr" rid="CR42">42</xref>] using BSA as standard protein.</p></sec><sec id="Sec8"><title>Determination of the Contents of GSx and GSSG</title><p id="Par12">The levels of cellular and extracellular GSx (amount of GSH&#x02009;+&#x02009;twice the amount of GSSG) and GSSG were assessed using a modified version of the colorimetric Tietze method adapted for 96-well microtiter plates, as previously described [<xref ref-type="bibr" rid="CR38">38</xref>]. Cell lysis was performed using 200 &#x000b5;L of 1% (w/v) sulfosalicylic acid and 10 &#x000b5;L of these lysates were utilized to quantify the cellular GSx and GSSG levels. To determine the extracellular GSx or GSSG contents, 10 &#x000b5;L of media samples were combined with 10 &#x000b5;L of 1% (w/v) sulfosalicylic acid, and this mixture was applied to the assays. The contribution of GSSG to the GSx values determined was quantified after removal of GSH from the samples by derivatization to 2-vinylpyridine as previous described [<xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec9"><title>WST1 Reduction by Astrocyte Cultures</title><p id="Par13">To examine the impact of itaconate, DI or OI on cell-mediated WST1 reduction, astrocyte cultures were washed twice with 1 mL of pre-warmed (37&#x000a0;&#x000b0;C) glucose-free IB and then preincubated for 30&#x000a0;min at 37&#x000a0;&#x000b0;C with 300 &#x000b5;L of glucose-free IB. Following a subsequent washing step with 300 &#x000b5;L of glucose-free IB, the cells were exposed to 300 &#x000b5;L of IB containing no or 5 mM glucose, in the presence of 3 &#x000b5;M of the redox cycler &#x003b2;-lapachone, 400 &#x000b5;M WST1 and itaconate, DI or OI at the indicated concentrations for up to 60&#x000a0;min in a humidified atmosphere (without CO<sub>2</sub>) in a cell incubator. After the given incubation periods, the incubation media were collected, and 50 &#x000b5;L samples were diluted with water to a total volume of 200 &#x000b5;L in the wells of a microtiter plate. The absorbance of the WST1 formazan produced was measured at 450&#x000a0;nm using a microtiter plate reader (Multiscan Sky, Thermo Fisher, Darmstadt, Germany) as previously reported [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. The specific accumulation of WST1 formazan was determined by normalizing the extracellular WST1 formazan content to the initial protein content of the respective cultures.</p></sec><sec id="Sec10"><title>Glucose and Lactate Determination in Incubation Media</title><p id="Par14">The glucose and lactate concentration in the incubation media were measured before and after the indicated periods of incubation using coupled enzymatic assays, as described previously [<xref ref-type="bibr" rid="CR38">38</xref>]. Glucose utilization was determined by subtracting the initial glucose concentration in the incubation buffer from the concentration measured after the given incubation period.</p></sec><sec id="Sec11"><title>Presentation of Data</title><p id="Par15">The presented data are means&#x02009;&#x000b1;&#x02009;standard deviation (SD) of values derived from experiments conducted in independent experiments on three separately prepared astrocyte cultures. Statistical analysis for differences among multiple data groups was performed using ANOVA followed by the Bonferroni post-hoc test. The t-test was used for comparing two data sets. A p-value greater than 0.05 was considered not significant.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Investigation of a Potential Alteration of the Astrocytic GSH Content and Export by Itaconate or its Derivatives</title><p id="Par16">To test whether an application of itaconate, DI or OI may affect cell viability and the cellular GSH metabolism, astrocyte primary cultures were incubated in the absence or the presence of itaconate, DI or OI in concentrations of 30 &#x000b5;M, 100 &#x000b5;M and 300 &#x000b5;M for up to 6&#x000a0;h. None of these incubations compromised the cell viability as demonstrated by the absence of any increase in extracellular LDH activity (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a-d). During the 6&#x000a0;h incubation, astrocytes that were incubated without itaconate, DI or OI exported about half of their GSH as shown by the decrease in the cellular GSx content from initially 48.4&#x02009;&#x000b1;&#x02009;1.6 nmol/mg protein to 25.1&#x02009;&#x000b1;&#x02009;2.2 nmol/mg protein (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>e) and by the appearance of 28.8&#x02009;&#x000b1;&#x02009;1.3 nmol GSx/mg protein in the incubation medium (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>i), while the sum of cellular plus extracellular GSx contents remained unaltered throughout the incubation period (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>m). The respective data for incubations of astrocytes with itaconate in concentrations of up to 300 &#x000b5;M were almost identical to those found in the absence of itaconate (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>e, i, m). In contrast, the presence of DI resulted in a time- and concentration-dependent loss in the cellular and extracellular GSx contents (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>f, j), thereby lowering the total amount (cellular plus extracellular values) of GSx in the cultures (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>n). Already after 4&#x000a0;h of incubation with 300 &#x000b5;M DI, the cells were almost completely deprived of GSx (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>f), and hardly any extracellular GSx was detectable for this condition (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>j). The exposure of astrocytes with OI resulted also in an accelerated loss of cellular GSx (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>g), but the determined decline in cellular GSx was accompanied by a matching increase in the extracellular GSx content (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>k) and the sum of cellular plus extracellular GSx contents remained unaltered throughout the entire incubation period for each of the applied concentrations of OI (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>o).</p><p id="Par17">Direct comparison of the data obtained for the 6&#x000a0;h incubations with itaconate, DI or OI revealed that itaconate in concentrations of up to 300 &#x000b5;M did not affect cellular (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>h) and extracellular (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>l) GSx contents, while both DI and OI accelerated cellular GSx loss in a concentration-dependent manner (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>h). However, both itaconate derivatives differed strongly in their effect on the extracellular accumulation of GSx, as OI accelerated extracellular GSx accumulation, while DI lowered this process in a concentration-dependent manner (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>l).</p><p id="Par18">GSx represents the sum of GSH plus twice the amount of GSSG [<xref ref-type="bibr" rid="CR38">38</xref>]. Analysis of the contribution of GSSG to the determined GSx contents for cells that had been treated without itaconate and its derivatives revealed that after a 6&#x000a0;h incubation, GSSG represented only around 3% of the determined cellular GSx and around 10% of the extracellular GSx (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), demonstrating that GSH accounts for the large majority of intra and extracellular GSx contents and that the cells were not under any oxidative stress, consistent with literature data [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. An exposure of astrocytes with itaconate or its derivatives DI or OI did also not cause any significant increase in specific GSSG values (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The apparent increase in the percental extracellular GSSG content of cells that had been treated with DI (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) is likely to be the consequence of the very low contents of GSx and GSSG determined for this condition which are in the range of the detection limit of the assay used.</p><p id="Par19">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Test for the consequences of an exposure with itaconate and its derivatives on the viability and the GSx content of cultured astrocytes. The cells were incubated without (0 &#x000b5;M) or with the given concentrations of itaconate, dimethyl itaconate or 4-octyl itaconate in a glucose-containing (5 mM) incubation buffer with 100 &#x000b5;M acivicin for up to 6&#x000a0;h. The extracellular LDH activity (<bold>a</bold>-<bold>d</bold>), the cellular (<bold>e</bold>-<bold>h</bold>) and extracellular (<bold>i</bold>-<bold>l</bold>) GSx contents and the sum of cellular plus extracellular GSx contents (<bold>m</bold>-<bold>p</bold>) were determined for the indicated incubation times. The initial specific cellular GSx content was 48.4&#x02009;&#x000b1;&#x02009;1.6 nmol/mg protein and the initial protein content of the cultures was 149&#x02009;&#x000b1;&#x02009;8&#x000a0;&#x000b5;g/well. The data presented are means&#x02009;&#x000b1;&#x02009;SD of values from experiments that had been performed on three independently prepared astrocyte cultures. The significance of differences (ANOVA) compared to the control incubation (absence of itaconate and its derivatives) is indicated by *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 in the colours of the respective symbols for the given concentrations. In the concentration dependencies shown for the three itaconates (d, h, l and p), the significance of differences (ANOVA) of values compared to the respective concentration of itaconate was calculated and is indicated by <sup>##</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 and <sup>###</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 in the colours of the symbols used for the itaconate derivatives</p></caption><graphic xlink:href="11064_2024_4263_Fig1_HTML" id="d33e589"/></fig>
</p><p id="Par20">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Test for the consequences of an exposure of cultured astrocytes with itaconate or its derivatives on the cellular and extracellular contents of GSx and GSSG</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Substance</th><th align="left" colspan="3">Cellular contents</th><th align="left" colspan="3">Extracellular contents</th></tr></thead><tbody><tr><td align="left"/><td align="left">GSx</td><td align="left">GSSG</td><td align="left">GSSG</td><td align="left">GSx</td><td align="left">GSSG</td><td align="left">GSSG</td></tr><tr><td align="left"/><td align="left">(nmol/mg)</td><td align="left">(nmol/mg)</td><td align="left">(% of GSx)</td><td align="left">(nmol/mg)</td><td align="left">(nmol/mg)</td><td align="left">(% of GSx)</td></tr><tr><td align="left">Control</td><td align="left">25.1&#x02009;&#x000b1;&#x02009;2.2</td><td align="left">0.8&#x02009;&#x000b1;&#x02009;0.3</td><td align="left">13&#x02009;&#x000b1;&#x02009;1</td><td align="left">28.8&#x02009;&#x000b1;&#x02009;1.3</td><td align="left">2.6&#x02009;&#x000b1;&#x02009;0.3</td><td align="left">9&#x02009;&#x000b1;&#x02009;1</td></tr><tr><td align="left">Itaconate</td><td align="left">24.4&#x02009;&#x000b1;&#x02009;2.6</td><td align="left">0.7&#x02009;&#x000b1;&#x02009;0.5</td><td align="left">13&#x02009;&#x000b1;&#x02009;2</td><td align="left">28.4&#x02009;&#x000b1;&#x02009;1.1</td><td align="left">2.4&#x02009;&#x000b1;&#x02009;0.1</td><td align="left">8&#x02009;&#x000b1;&#x02009;1</td></tr><tr><td align="left">Dimethyl itaconate</td><td align="left">0.0&#x02009;&#x000b1;&#x02009;0.0***</td><td align="left">0.6&#x02009;&#x000b1;&#x02009;0.2</td><td align="left">n. c.</td><td align="left">1.9&#x02009;&#x000b1;&#x02009;0.2***</td><td align="left">0.5&#x02009;&#x000b1;&#x02009;0.1***</td><td align="left">25&#x02009;&#x000b1;&#x02009;9**</td></tr><tr><td align="left">4-octyl itaconate</td><td align="left">6.9&#x02009;&#x000b1;&#x02009;2.5***</td><td align="left">0.6&#x02009;&#x000b1;&#x02009;0.2</td><td align="left">10&#x02009;&#x000b1;&#x02009;5</td><td align="left">41.2&#x02009;&#x000b1;&#x02009;2.2***</td><td align="left">3.2&#x02009;&#x000b1;&#x02009;0.4</td><td align="left">8&#x02009;&#x000b1;&#x02009;1</td></tr></tbody></table><table-wrap-foot><p>The cells were incubated without (0 &#x000b5;M) or with 300 &#x000b5;M itaconate, dimethyl itaconate or 4-octyl itaconate in a glucose-containing (5 mM) incubation buffer with 100 &#x000b5;M acivicin for 6&#x000a0;h before the cellular and extracellular contents of GSx and GSSG were determined. The initial specific GSx content was 48.4&#x02009;&#x000b1;&#x02009;1.6 nmol/mg protein and the initial protein content of the cultures was 149&#x02009;&#x000b1;&#x02009;8&#x000a0;&#x000b5;g/well. The data presented are means&#x02009;&#x000b1;&#x02009;SD of values from experiments that had been performed on three independently prepared astrocyte cultures. The GSx contents are those already shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The significance of differences (ANOVA) compared to the control incubation (none) is indicated by *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. n.c. = not calculable</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Effects of the Mrp1-inhibitor MK571 on the GSx Export for OI-treated Astrocytes</title><p id="Par21">GSH export from astrocytes is mainly mediated by Mrp1 [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. To test whether Mrp1 is involved in the stimulated GSH export observed for OI-treated astrocytes, the cells were incubated for 4&#x000a0;h without or with itaconate or its derivatives in the absence or the presence of the Mrp1 inhibitor MK571. In the absence of itaconate, DI and OI, the cells exported within 4&#x000a0;h about 38% of their initial cellular GSx content resulting in cellular and extracellular GSx values of 32.0&#x02009;&#x000b1;&#x02009;7.5 nmol/mg protein and 18.7&#x02009;&#x000b1;&#x02009;0.3 nmol/mg protein, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a, b). In contrast, after incubation with 50 &#x000b5;M MK571 for 4&#x000a0;h, the extracellular GSx content was with 10.0&#x02009;&#x000b1;&#x02009;1.3 nmol/mg protein (20% of the initial cellular GSx content) half of that found for the respective incubation without MK571 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). Incubation with MK571 did not alter the sum of cellular plus extracellular GSx levels compared to the control condition (absence of MK571) which remained similar to the initial cellular GSx content (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c). Almost identical results to that of the incubation of control cells (absence of itaconate, DI and OI) were found for incubations of astrocytes with 300 &#x000b5;M itaconate in the absence or the presence of MK571 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a-c).</p><p id="Par22">After a 4&#x000a0;h incubation of astrocytes with 300 &#x000b5;M DI, neglectably small amounts of cellular and extracellular GSx levels were detected (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a-c). The presence of MK571 appears to prevent part of the cellular GSx loss, but the observed difference did not reach the level of significance (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). In contrast, the accelerated loss in cellular GSx of OI-treated astrocytes and the stimulated extracellular accumulation of GSx were completely prevented by the presence of MK571 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a, b), resulting in total (cellular plus extracellular) GSx contents that were nearly identical to the contents of control cells that had been incubated in the absence of OI (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c). None of the conditions used compromised cell viability as demonstrated by the absence of any increase in extracellular LDH activity (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d).</p><p id="Par23">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Test for the consequences of a MK571-mediated Mrp1 inhibition on the cellular and extracellular GSx contents of itaconate-treated astrocytes. The cells were incubated in a glucose-containing (5 mM) incubation buffer for 4&#x000a0;h without (none) or with 300 &#x000b5;M of itaconate (IT), dimethyl itaconate (DI) or 4-octyl itaconate (OI) with 100 &#x000b5;M acivicin in the absence (control) or the presence of 50 &#x000b5;M of the Mrp1 inhibitor MK571. The cellular (<bold>a</bold>) and extracellular (<bold>b</bold>) contents of GSx, the sum of cellular plus extracellular GSx contents (<bold>c</bold>), and the extracellular LDH activity (<bold>d</bold>) were determined. The initial specific GSx content was 49.5&#x02009;&#x000b1;&#x02009;5.9 nmol/mg protein and the initial protein content of the cultures was 150&#x02009;&#x000b1;&#x02009;17&#x000a0;&#x000b5;g per well. The data presented are means&#x02009;&#x000b1;&#x02009;SD of values from experiments that had been performed on three independently prepared astrocyte cultures. The significance of differences (ANOVA) compared to the respective control incubation (none) was analysed and is indicated by **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. The significance of differences (t-test) of data obtained for incubations in the absence or the presence of MK571 is indicated by <sup>#</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 and <sup>##</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p></caption><graphic xlink:href="11064_2024_4263_Fig2_HTML" id="d33e795"/></fig>
</p></sec><sec id="Sec15"><title>Test for Cell-independent Chemical Reaction of GSH with Itaconate and its Derivatives</title><p id="Par24">In order to investigate whether GSH chemically reacts in the absence of cells with itaconate or its derivatives under the conditions used for cell experiments, 10 &#x000b5;M GSH were incubated with a large excess of itaconate, DI or OI for up to 4&#x000a0;h. Excess of itaconate or OI did hardly affect the detectable amount of GSH during the incubation (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, c), while the presence of DI lowered in a time-dependent manner the detectable amount of GSH within 4&#x000a0;h by 31% (1 mM DI) and by 88% (10 mM DI) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b).</p><p id="Par25">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Test for cell-independent reactions between GSH and itaconate, dimethyl itaconate or octyl itaconate. GSH (10 &#x000b5;M) was incubated without (0 mM) or with 1 mM or 10 mM itaconate, DI or OI in 1 mL IB for up to 240&#x000a0;min. The GSH content was determined for the indicated time points. The data presented are means&#x02009;&#x000b1;&#x02009;SD of values from three independent experiments. The significance of differences (ANOVA) compared to the respective control incubation (absence of itaconate and its derivatives) was analysed and is indicated by *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="11064_2024_4263_Fig3_HTML" id="d33e825"/></fig>
</p></sec><sec id="Sec16"><title>Investigation of a Potential Interference of Itaconates with the Glycolytic Lactate Production in Astrocytes</title><p id="Par26">To test for a potential effect on the glycolytic lactate production, cultured astrocytes were exposed to 5 mM glucose without or with itaconate, DI or OI in concentrations of up to 300 &#x000b5;M for up to 6&#x000a0;h. During incubation of control cells (absence of itaconate and its derivatives), lactate accumulated almost proportional to time for up to 6&#x000a0;h in the incubation medium (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). After 6&#x000a0;h, the cells had released 6.0&#x02009;&#x000b1;&#x02009;0.7 &#x000b5;mol lactate/mg protein (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a-c) and had consumed 3.7&#x02009;&#x000b1;&#x02009;0.1 &#x000b5;mol glucose/mg protein (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d). The presence of itaconate or DI in concentrations of up to 300 &#x000b5;M during the incubation did not alter lactate release (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, b) nor glucose consumption (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d), compared to the results obtained for control cells. In contrast, incubation of astrocyte primary cultures with OI resulted in significantly elevated extracellular lactate contents already after 1&#x000a0;h of incubation with 30 &#x000b5;M OI (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c). After 6&#x000a0;h of incubation with 300 &#x000b5;M OI, the cellular lactate release was found increased by 33% to values of 8.0&#x02009;&#x000b1;&#x02009;0.8 &#x000b5;mol lactate/mg protein (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c), and the specific glucose consumption was significantly increased by around 20% compared to control conditions (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d). The ratio of lactate released to glucose consumed remained unaltered for all tested substances and conditions (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>e). None of the conditions applied caused any substantial increase in the extracellular LDH activity (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>f), demonstrating that the cell viability was not compromised.</p><p id="Par27">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Test for potential effects of itaconate and its derivatives on the glycolytic lactate generation by cultured astrocytes. The cells were incubated without (0 &#x000b5;M) or with the given concentrations of itaconate (<bold>a</bold>, <bold>d</bold>-<bold>f</bold>), dimethyl itaconate (<bold>b</bold>, <bold>d</bold>-<bold>f</bold>) or octyl itaconate (<bold>c</bold>, <bold>d</bold>-<bold>f</bold>) in a glucose-containing (5 mM) incubation buffer with 100 &#x000b5;M acivicin for up to 6&#x000a0;h. The specific extracellular lactate content (<bold>a</bold>-<bold>c</bold>) and the extracellular LDH activity for the 6&#x000a0;h incubation period (<bold>f</bold>) was determined for the indicated time points. In addition, the specific glucose consumption (<bold>d</bold>) and the ratio of lactate release to glucose consumption (<bold>e</bold>) were calculated for the 6&#x000a0;h values. The initial protein content of the cultures was 136&#x02009;&#x000b1;&#x02009;22&#x000a0;&#x000b5;g/well. The data shown represent means&#x02009;&#x000b1;&#x02009;SD of values from experiments that had been performed on three independently prepared astrocyte cultures. The significance of differences (ANOVA) compared to the control incubation (0 &#x000b5;M) is indicated by *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 in the colours of the symbols used for the respective concentrations or compounds</p></caption><graphic xlink:href="11064_2024_4263_Fig4_HTML" id="d33e924"/></fig>
</p></sec><sec id="Sec17"><title>Test for Potential Interference of Itaconates with the &#x000df;-lapachone-mediated WST1 Reduction</title><p id="Par28">Astrocytic NQO1-dependent and &#x003b2;-lapachone-mediated WST1 reduction is mainly fuelled by NADPH that is generated from glucose-6-phosphate in the PPP [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. In order to investigate whether itaconate, DI or OI may affect the astrocytic reduction of WST1 to WST1 formazan, astrocyte cultures were incubated with &#x003b2;-lapachone and WST1 in the absence or the presence of 100 &#x000b5;M or 300 &#x000b5;M of itaconate, DI or OI for up to 60&#x000a0;min. In the absence (0 &#x000b5;M) of itaconate, DI and OI a time-dependent linear increase in extracellular WST1 formazan was observed that reached after 60&#x000a0;min nearly 400 nmol/mg protein (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a-c). This WST1 reduction by astrocytes was not affected by the presence of 100 &#x000b5;M or 300 &#x000b5;M itaconate, DI or OI (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a-c; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In contrast, the presence of the glucose-6-phosphate dehydrogenase (G6PDH) inhibitor G6PDi-1 [<xref ref-type="bibr" rid="CR46">46</xref>] significantly lowered the cellular WST1 reduction by around 55% (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Co-application of 300 &#x000b5;M of itaconate, DI or OI with G6PDi-1 did neither alter the inhibitory potential of G6PD-1 on WST1 reduction nor the rate of G6PDH-independent (data determined in the presence of G6PDi-1; [<xref ref-type="bibr" rid="CR46">46</xref>]) electron supply for WST1 reduction (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par29">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Test for potential effects of itaconate and its derivatives to affect the &#x003b2;-lapachone-mediated WST1 reduction of cultured astrocytes. The cells were pre-incubated in a glucose-free incubation buffer for 30&#x000a0;min and subsequently incubated without (0 &#x000b5;M) or with 100 &#x000b5;M or 300 &#x000b5;M of itaconate (<bold>a</bold>), dimethyl itaconate (<bold>b</bold>) or 4-octyl itaconate (<bold>c</bold>) in a glucose-containing (5 mM) incubation buffer containing 3 &#x000b5;M &#x003b2;-lapachone and 400 &#x000b5;M WST1 for up to 60&#x000a0;min. The extracellular WST1 formazan content was determined after the indicated time points. The initial protein content of the cultures was 128&#x02009;&#x000b1;&#x02009;18&#x000a0;&#x000b5;g per well. None of the conditions used increased the extracellular LDH activity significantly (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The data presented are means&#x02009;&#x000b1;&#x02009;SD of values from experiments that had been performed on three independently prepared astrocyte cultures. The differences of data obtained for the different concentrations and between the tested compounds was not significant (ANOVA)</p></caption><graphic xlink:href="11064_2024_4263_Fig5_HTML" id="d33e979"/></fig>
</p><p id="Par30">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Test for potential effects of itaconate and its derivatives on the G6PDH-independent &#x003b2;-lapachone-mediated WST1 reduction by cultured astrocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">Control</th><th align="left" colspan="2">G6PDi-1</th></tr></thead><tbody><tr><td align="left">Compound tested</td><td align="left"><p>LDH</p><p>(%)</p></td><td align="left"><p>WST1 formazan</p><p>(nmol/mg protein)</p></td><td align="left"><p>LDH</p><p>(%)</p></td><td align="left"><p>WST1 formazan</p><p>(nmol/mg protein)</p></td></tr><tr><td align="left">None</td><td align="left">5&#x02009;&#x000b1;&#x02009;9</td><td align="left">390&#x02009;&#x000b1;&#x02009;59</td><td align="left">3&#x02009;&#x000b1;&#x02009;4</td><td align="left">174&#x02009;&#x000b1;&#x02009;33<sup>##</sup></td></tr><tr><td align="left">Itaconate</td><td align="left">1&#x02009;&#x000b1;&#x02009;1</td><td align="left">362&#x02009;&#x000b1;&#x02009;49</td><td align="left">2&#x02009;&#x000b1;&#x02009;3</td><td align="left">160&#x02009;&#x000b1;&#x02009;36<sup>##</sup></td></tr><tr><td align="left">Dimethyl itaconate</td><td align="left">1&#x02009;&#x000b1;&#x02009;2</td><td align="left">381&#x02009;&#x000b1;&#x02009;67</td><td align="left">4&#x02009;&#x000b1;&#x02009;5</td><td align="left">175&#x02009;&#x000b1;&#x02009;36<sup>##</sup></td></tr><tr><td align="left">4-Octyl itaconate</td><td align="left">5&#x02009;&#x000b1;&#x02009;3</td><td align="left">382&#x02009;&#x000b1;&#x02009;46</td><td align="left">3&#x02009;&#x000b1;&#x02009;2</td><td align="left">168&#x02009;&#x000b1;&#x02009;26<sup>##</sup></td></tr></tbody></table><table-wrap-foot><p>The cells were pre-incubated in a glucose-free incubation buffer for 30&#x000a0;min and subsequently incubated for 60&#x000a0;min without (None) or with 300 &#x000b5;M of itaconate, dimethyl itaconate or 4-octyl itaconate in a glucose-containing (5 mM) incubation buffer (containing 3 &#x000b5;M &#x003b2;-lapachone and 400 &#x000b5;M WST1) in the absence (Control) or the presence (30 &#x000b5;M) of the G6PDH inhibitor G6PDi-1 before the extracellular LDH activity (given as % of the initial cellular LDH activity) and the specific WST1 formazan formation were determined. The data for the WST1 formazan formation in the absence of G6PDi-1 are those already shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>. The initial protein content of the cultures was 128&#x02009;&#x000b1;&#x02009;18&#x000a0;&#x000b5;g per well. The data presented are means&#x02009;&#x000b1;&#x02009;SD of values from experiments that had been performed on three independently prepared astrocyte cultures. The significance of differences (ANOVA) of data compared to those of the control incubation (None) was tested, but no significant differences were observed. The significance of differences (t-test) of data obtained for incubations in the absence or the presence of G6PDi-1 is indicated by <sup>##</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec18" sec-type="discussion"><title>Discussion</title><p id="Par31">Primary astrocyte cultures were used to investigate potential adverse consequences of an exposure of astrocytes to itaconate, DI or OI on cell viability, GSH metabolism and glucose metabolism. None of the conditions investigated caused a substantial increase in extracellular LDH activity, demonstrating that incubations of up to 6&#x000a0;h with itaconate, DI or OI in concentrations of up to 300 &#x000b5;M do not compromise cell viability. This confirms the low cell toxic potential of these compounds reported for various cell types [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>]. In addition, the absence of any detectable increase in cellular GSSG contents in treated astrocytes demonstrates that the presence of itaconate, DI or OI does not cause any detectable oxidative stress under the conditions used. This was expected as itaconate and its derivatives have been reported to rather improve antioxidative defense by activation of Nrf2 in different cell types [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>] including astrocytes [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par32">Application of itaconate in concentrations of up to 300 &#x000b5;M for up to 6&#x000a0;h did not affect the cellular GSH metabolism, the GSH export, the cytosolic glucose metabolism via glycolysis or PPP. Similarly, after exposure of 250 &#x000b5;M itaconate to unstimulated bone marrow-derived macrophages the cellular GSH content has been reported to remain unaltered and formation of itaconate-GSH conjugates was not found [<xref ref-type="bibr" rid="CR54">54</xref>]. Due to the low membrane permeability of itaconate [<xref ref-type="bibr" rid="CR47">47</xref>], the micromolar concentration of extracellular itaconate applied in the present study appears to be insufficient to cause sufficiently high cellular concentrations that are able to affect the metabolic processes investigated.</p><p id="Par33">An increase in endogenous itaconate levels after experimental stroke has very recently been linked to a decrease in pyruvate contents, supporting the hypothesis that itaconate acts as glycolysis inhibitor via competitive inhibition of pyruvate kinase [<xref ref-type="bibr" rid="CR55">55</xref>]. Considering the low concentrations of itaconate applied in our study (up to 300 &#x000b5;M) and the low membrane permeability of itaconate, the cellular concentration established by the extracellular application of itaconate to cultured astrocytes may be too low to affect glycolysis. Further studies are now required to test for the potential of endogenously produced itaconate to affect the metabolism of astrocytes.</p><p id="Par34">DI and OI have frequently been applied as membrane permeable derivatives of itaconate to study potential effects of itaconate on astrocytes [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] and other cell types [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Indeed, application of these compounds affected astrocytic GSH and glucose metabolism. It is assumed that after uptake into cells the ester bonds of DI and OI are hydrolyzed by esterases and itaconate is liberated to affect cell functions [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. As such hydrolysis of DI or OI will in addition to itaconate also liberate the alcohols methanol or octanol, respectively, a potential contribution of these alcohols to the metabolic effects observed has to be considered. However, as the presence of 300 &#x000b5;M octanol (data not shown) or of up to 1 mM methanol [<xref ref-type="bibr" rid="CR63">63</xref>] did not affect glycolytic lactate production nor astrocytic GSH metabolism or transport, a potential effect of the alcohols liberated from DI or OI on the parameters investigated in the current study can be excluded.</p><p id="Par35">DI and OI have been reported to affect cytosolic glucose metabolism and mitochondrial energy production in several cell types [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR58">58</xref>] and the modification of metabolic enzymes by alkylation through the itaconate liberated from the itaconate esters has been discussed to contribute to the reported effects [<xref ref-type="bibr" rid="CR56">56</xref>]. For cultured astrocytes, the presence of DI did not acutely affect glucose consumption, glycolytic lactate generation nor the supply of electrons by the PPP or other pathways for WST1 reduction, suggesting that for the conditions studied astrocytic enzymes are not rapidly modified by the presence of DI to an extend that would lead to detectable alterations of the processes investigated.</p><p id="Par36">The presence of OI accelerated glycolytic lactate production by cultured astrocytes as reported previously for many drugs that inhibit mitochondrial processes [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], suggesting that also the observed acceleration of lactate production by OI-treated astrocytes may be the consequence of mitochondrial impairment. This would be consistent with literature data reporting that itaconate inhibits succinate dehydrogenase due to its structural similarity to succinate [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. In astrocytes, the itaconate required for such an inhibition could be generated by hydrolysis from uptaken OI, as reported for other cells [<xref ref-type="bibr" rid="CR49">49</xref>]. For LPS-stimulated macrophages and colorectal cancer cells was shown that presence of OI rather inhibits glycolysis and that this effect is caused by alkylation of the catalytically active cysteine residue in the active center of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Such an inhibition appears not to take place in OI-treated astrocytes as glycolytic lactate production was not lowered but rather accelerated. However, it should be considered that GAPDH is present in high activity in cultured astrocytes and that the activity of this enzyme has to be inhibited by more than 80% before an impairment of glycolytic lactate production is observed [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par37">The normal slow loss of cellular GSH from cultured astrocytes [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] was found accelerated in a time- and concentration-dependent manner by the presence of either DI or OI. However, different mechanisms appear to be responsible for the loss in cellular GSH in presence of the two itaconate esters. Presence of DI caused a decline in GSH contents in both the cells and the medium. As an excess of DI also depleted GSH in a cell-free setting, it is likely that GSH reacts as nucleophile with the &#x003b1;,&#x003b2;-unsaturated carboxylate in a Michael-type addition to form a 2,3-dicarboxypropyl adduct. A similar alkylation of GSH like that found for DI-treated astrocytes has been reported for fumaric acid diesters for cells and cell-free conditions [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. In contrast to DI, GSH disappearance in cell-free conditions was not found for an excess of OI, consistent with the much lower reactivity of the charged monoesters of itaconate and fumarate with thiols such as GSH [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR66">66</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref>]. Although such Michael-type chemical reaction with GSH can be expected for all &#x003b1;,&#x003b2;-unsaturated carboxylates [<xref ref-type="bibr" rid="CR56">56</xref>], itaconate and OI have been reported to have far lower reactivity towards thiols than DI [<xref ref-type="bibr" rid="CR49">49</xref>], explaining why the total GSH content of the treated cultures (cellular plus extracellular content) is only lowered by DI but not by itaconate or OI. Further studies are now required to confirm that indeed a conjugation product between DI and GSH is formed after application of DI to cultured astrocytes and whether this conjugate is further metabolized and/or exported by the cells. It also remains to be elucidated whether in astrocytes the chemical derivatization of GSH in the presence of DI is accelerated by cellular glutathione-S-transferases, which are known to catalyze the reaction of GSH with unsaturated compounds [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par38">The accelerated loss in cellular GSH in OI-treated astrocytes was accompanied by a matching increase in the extracellular GSH content, suggesting that the presence of OI stimulates the export of GSH. A similar stimulation of GSH export from cultured astrocytes has been reported for treatments with formaldehyde [<xref ref-type="bibr" rid="CR71">71</xref>] or antiretroviral protease inhibitors [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>] and was shown to be mediated by Mrp1. The application of the Mrp1 inhibitor MK571 [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] completely prevented the OI-stimulated GSH export, demonstrating that also the presence of OI accelerates Mrp1-mediated GSH export from astrocytes. Similar to the endogenous Mrp1 substrate leukotriene C4 [<xref ref-type="bibr" rid="CR74">74</xref>], OI contains a hydrophobic octyl-group as well as a polar carboxyl-group. Due to the bipartite binding site of Mrp1 [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR74">74</xref>], such structural features of OI facilitate binding of compounds to Mrp1 which stimulate GSH transport from astrocytes [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par39">Itaconate has recently been reported to stimulate the OXGR1 receptor in the respiratory epithelium in a mouse model of pulmonary infection with bacteria [<xref ref-type="bibr" rid="CR6">6</xref>], demonstrating that itaconate can have extracellular functions as ligand of a receptor. As the presence of OXGR1 mRNA in human brain cells has been reported [<xref ref-type="bibr" rid="CR75">75</xref>], itaconate might also act as extracellular signaling molecule in brain. This option should be addressed in further studies and a possible differential potential of itaconate, DI or OI to activate OXGR1 and to modify immune responses in brain cells needs to be elucidated [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par40">In conclusion, an exposure of cultured astrocytes to itaconate or its membrane-permeable esters DI or OI in concentrations of up to 300 &#x000b5;M did not cause any acute oxidative stress, did not compromise cell viability and did not affect electron supply via the PPP for cell-dependent WST1 reduction. However, the three tested compounds differed strongly concerning their potential to affect glycolytic lactate production, the cellular GSH content and the GSH export. While applied itaconate did not affect the cellular pathways investigated, OI stimulated glycolytic lactate production and Mrp1-mediated GSH export. In contrast, DI depleted the cultures of GSH, most likely by chemical addition of the thiol to the double bond of DI. These strong differences in the consequences of a treatment of astrocytes with itaconate, DI and OI should be considered for future studies that use itaconate esters such as DI and OI as potential extracellular sources to increase cellular itaconate levels as well as for the design of strategies to use itaconate esters as therapeutic agents to limit detrimental effects after ischemic brain injury or stroke.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>CA and RD developed the study concept and design. PW performed all experiments shown and prepared the first draft of the figures. GKK performed initial experiments on the consequences of a treatment of astrocytes with itaconates. CA prepared the final figures, calculated statistics and wrote the manuscript. All authors reviewed and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing Interests</title><p id="Par41">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Strelko</surname><given-names>CL</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Dufort</surname><given-names>FJ</given-names></name><name><surname>Seyfried</surname><given-names>TN</given-names></name><name><surname>Chiles</surname><given-names>TC</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Roberts</surname><given-names>MF</given-names></name></person-group><article-title>Itaconic acid is a mammalian metabolite induced during macrophage activation</article-title><source>J Am Chem Soc</source><year>2011</year><volume>133</volume><fpage>16386</fpage><lpage>16389</lpage><pub-id pub-id-type="pmid">21919507</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Strelko CL, Lu W, Dufort FJ, Seyfried TN, Chiles TC, Rabinowitz JD, Roberts MF (2011) Itaconic acid is a mammalian metabolite induced during macrophage activation. J Am Chem Soc 133:16386&#x02013;16389<pub-id pub-id-type="pmid">21919507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, Binz T, Wegner A, Tallam A, Rausell A, Buttini M, Linster CL, Medina E, Balling R, Hiller K (2013) Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proceedings of the National Academy of Sciences 110:7820&#x02013;7825</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Peace</surname><given-names>CG</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>LA</given-names></name></person-group><article-title>The role of itaconate in host defense and inflammation</article-title><source>J Clin Invest</source><year>2022</year><volume>132</volume><fpage>e148548</fpage><pub-id pub-id-type="pmid">35040439</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Peace CG, O&#x02019;Neill LA (2022) The role of itaconate in host defense and inflammation. J Clin Invest 132:e148548<pub-id pub-id-type="pmid">35040439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Lin J, Ren J, Gao DS, Dai Y, Yu L (2021) The emerging application of itaconate: promising molecular targets and therapeutic opportunities. Front Chem 9:669308</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name></person-group><article-title>Itaconate: a promising precursor for treatment of neuroinflammation associated depression</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>167</volume><fpage>115521</fpage><pub-id pub-id-type="pmid">37717531</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Liu R, Gong Y, Xia C, Cao Y, Zhao C, Zhou M (2023) Itaconate: a promising precursor for treatment of neuroinflammation associated depression. Biomed Pharmacother 167:115521<pub-id pub-id-type="pmid">37717531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Zeng Y-R, Song J-B, Wang D, Huang Z-X, Zhang C, Sun Y-P, Shu G, Xiong Y, Guan K-L, Ye D (2023) The immunometabolite itaconate stimulates OXGR1 to promote mucociliary clearance during the pulmonary innate immune response. J Clin Investig 133</mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000e4;kel</surname><given-names>S</given-names></name><name><surname>Dimou</surname><given-names>L</given-names></name></person-group><article-title>Glial cells and their function in the adult brain: a journey through the history of their ablation</article-title><source>Front Cell Neurosci</source><year>2017</year><volume>11</volume><fpage>24</fpage><pub-id pub-id-type="pmid">28243193</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">J&#x000e4;kel S, Dimou L (2017) Glial cells and their function in the adult brain: a journey through the history of their ablation. Front Cell Neurosci 11:24<pub-id pub-id-type="pmid">28243193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Barros</surname><given-names>LF</given-names></name></person-group><article-title>The astrocyte: powerhouse and recycling center</article-title><source>Cold Spring Harb Perspect Biol</source><year>2015</year><pub-id pub-id-type="doi">10.1101/cshperspect.a020396:a020396</pub-id><pub-id pub-id-type="pmid">25680832</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Weber B, Barros LF (2015) The astrocyte: powerhouse and recycling center. Cold Spring Harb Perspect Biol. 10.1101/cshperspect.a020396:a020396<pub-id pub-id-type="pmid">25680832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Marina</surname><given-names>N</given-names></name><name><surname>Turovsky</surname><given-names>E</given-names></name><name><surname>Christie</surname><given-names>IN</given-names></name><name><surname>Hosford</surname><given-names>PS</given-names></name><name><surname>Hadjihambi</surname><given-names>A</given-names></name><name><surname>Korsak</surname><given-names>A</given-names></name><name><surname>Ang</surname><given-names>R</given-names></name><name><surname>Mastitskaya</surname><given-names>S</given-names></name><name><surname>Sheikhbahaei</surname><given-names>S</given-names></name><name><surname>Theparambil</surname><given-names>SM</given-names></name></person-group><article-title>Brain metabolic sensing and metabolic signaling at the level of an astrocyte</article-title><source>Glia</source><year>2018</year><volume>66</volume><fpage>1185</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">29274121</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Marina N, Turovsky E, Christie IN, Hosford PS, Hadjihambi A, Korsak A, Ang R, Mastitskaya S, Sheikhbahaei S, Theparambil SM (2018) Brain metabolic sensing and metabolic signaling at the level of an astrocyte. Glia 66:1185&#x02013;1199<pub-id pub-id-type="pmid">29274121</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Beard</surname><given-names>E</given-names></name><name><surname>Lengacher</surname><given-names>S</given-names></name><name><surname>Dias</surname><given-names>S</given-names></name><name><surname>Magistretti</surname><given-names>PJ</given-names></name><name><surname>Finsterwald</surname><given-names>C</given-names></name></person-group><article-title>Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives</article-title><source>Front Physiol</source><year>2022</year><volume>12</volume><fpage>825816</fpage><pub-id pub-id-type="pmid">35087428</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Beard E, Lengacher S, Dias S, Magistretti PJ, Finsterwald C (2022) Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives. Front Physiol 12:825816<pub-id pub-id-type="pmid">35087428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Leng</surname><given-names>L</given-names></name></person-group><article-title>Brain energy metabolism: astrocytes in neurodegenerative diseases</article-title><source>CNS Neurosci Ther</source><year>2023</year><volume>29</volume><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">36193573</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chen Z, Yuan Z, Yang S, Zhu Y, Xue M, Zhang J, Leng L (2023) Brain energy metabolism: astrocytes in neurodegenerative diseases. CNS Neurosci Ther 29:24&#x02013;36<pub-id pub-id-type="pmid">36193573</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Burda</surname><given-names>JE</given-names></name><name><surname>Bernstein</surname><given-names>AM</given-names></name><name><surname>Sofroniew</surname><given-names>MV</given-names></name></person-group><article-title>Astrocyte roles in traumatic brain injury</article-title><source>Exp Neurol</source><year>2016</year><volume>275</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">25828533</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Burda JE, Bernstein AM, Sofroniew MV (2016) Astrocyte roles in traumatic brain injury. Exp Neurol 275:305&#x02013;315<pub-id pub-id-type="pmid">25828533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name></person-group><article-title>The specific role of reactive astrocytes in stroke</article-title><source>Front Cell Neurosci</source><year>2022</year><volume>16</volume><fpage>850866</fpage><pub-id pub-id-type="pmid">35321205</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Li L, Zhou J, Han L, Wu X, Shi Y, Cui W, Zhang S, Hu Q, Wang J, Bai H (2022) The specific role of reactive astrocytes in stroke. Front Cell Neurosci 16:850866<pub-id pub-id-type="pmid">35321205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Giraldo</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez-Reyes</surname><given-names>RE</given-names></name><name><surname>Ram&#x000ed;rez-Guerrero</surname><given-names>S</given-names></name><name><surname>Bonilla-Trilleras</surname><given-names>CE</given-names></name><name><surname>Guardo-Maya</surname><given-names>S</given-names></name><name><surname>Nava-Mesa</surname><given-names>MO</given-names></name></person-group><article-title>Astrocytes as a therapeutic target in alzheimer&#x02019;s disease&#x02013;comprehensive review and recent developments</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>13630</fpage><pub-id pub-id-type="pmid">36362415</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Rodr&#x000ed;guez-Giraldo M, Gonz&#x000e1;lez-Reyes RE, Ram&#x000ed;rez-Guerrero S, Bonilla-Trilleras CE, Guardo-Maya S, Nava-Mesa MO (2022) Astrocytes as a therapeutic target in alzheimer&#x02019;s disease&#x02013;comprehensive review and recent developments. Int J Mol Sci 23:13630<pub-id pub-id-type="pmid">36362415</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X-Y</given-names></name><name><surname>Gao</surname><given-names>Z-K</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>Y-S</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name></person-group><article-title>Activation and role of astrocytes in ischemic stroke</article-title><source>Front Cell Neurosci</source><year>2021</year><volume>15</volume><fpage>755955</fpage><pub-id pub-id-type="pmid">34867201</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Shen X-Y, Gao Z-K, Han Y, Yuan M, Guo Y-S, Bi X (2021) Activation and role of astrocytes in ischemic stroke. Front Cell Neurosci 15:755955<pub-id pub-id-type="pmid">34867201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>JJ</given-names></name></person-group><article-title>Blood-brain barrier (bbb) and the complement landscape</article-title><source>Mol Immunol</source><year>2018</year><volume>102</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">30007547</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Alexander JJ (2018) Blood-brain barrier (bbb) and the complement landscape. Mol Immunol 102:26&#x02013;31<pub-id pub-id-type="pmid">30007547</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>NJ</given-names></name><name><surname>Eroglu</surname><given-names>C</given-names></name></person-group><article-title>Cell biology of astrocyte-synapse interactions</article-title><source>Neuron</source><year>2017</year><volume>96</volume><fpage>697</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">29096081</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Allen NJ, Eroglu C (2017) Cell biology of astrocyte-synapse interactions. Neuron 96:697&#x02013;708<pub-id pub-id-type="pmid">29096081</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Saint-Martin</surname><given-names>M</given-names></name><name><surname>Goda</surname><given-names>Y</given-names></name></person-group><article-title>Astrocyte&#x02013;synapse interactions and cell adhesion molecules</article-title><source>FEBS J</source><year>2022</year><pub-id pub-id-type="doi">10.1111/febs.16540</pub-id><pub-id pub-id-type="pmid">35647709</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Saint-Martin M, Goda Y (2022) Astrocyte&#x02013;synapse interactions and cell adhesion molecules. FEBS J. 10.1111/febs.16540<pub-id pub-id-type="pmid">35647709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>McBean</surname><given-names>G</given-names></name></person-group><article-title>Cysteine, glutathione, and thiol redox balance in astrocytes</article-title><source>Antioxidants</source><year>2017</year><volume>6</volume><fpage>62</fpage><pub-id pub-id-type="pmid">28771170</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">McBean G (2017) Cysteine, glutathione, and thiol redox balance in astrocytes. Antioxidants 6:62<pub-id pub-id-type="pmid">28771170</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Aoyama</surname><given-names>K</given-names></name></person-group><article-title>Glutathione in the brain</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>5010</fpage><pub-id pub-id-type="pmid">34065042</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Aoyama K (2021) Glutathione in the brain. Int J Mol Sci 22:5010<pub-id pub-id-type="pmid">34065042</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Dringen</surname><given-names>R</given-names></name><name><surname>Hamprecht</surname><given-names>B</given-names></name></person-group><article-title>Glutathione restoration as indicator for cellular metabolism of astroglial cells</article-title><source>Dev Neurosci</source><year>1998</year><volume>20</volume><fpage>401</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">9778578</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Dringen R, Hamprecht B (1998) Glutathione restoration as indicator for cellular metabolism of astroglial cells. Dev Neurosci 20:401&#x02013;407<pub-id pub-id-type="pmid">9778578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirrlinger</surname><given-names>J</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>J</given-names></name><name><surname>Keppler</surname><given-names>D</given-names></name><name><surname>Lindenau</surname><given-names>J</given-names></name><name><surname>Schulz</surname><given-names>JB</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress</article-title><source>J Neurochem</source><year>2001</year><volume>76</volume><fpage>627</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">11208926</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Hirrlinger J, K&#x000f6;nig J, Keppler D, Lindenau J, Schulz JB, Dringen R (2001) The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J Neurochem 76:627&#x02013;636<pub-id pub-id-type="pmid">11208926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Raabe</surname><given-names>J</given-names></name><name><surname>Arend</surname><given-names>C</given-names></name><name><surname>Steinmeier</surname><given-names>J</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Dicoumarol inhibits multidrug resistance protein 1-mediated export processes in cultured primary rat astrocytes</article-title><source>Neurochem Res</source><year>2019</year><volume>44</volume><fpage>333</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">30443714</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Raabe J, Arend C, Steinmeier J, Dringen R (2019) Dicoumarol inhibits multidrug resistance protein 1-mediated export processes in cultured primary rat astrocytes. Neurochem Res 44:333&#x02013;346<pub-id pub-id-type="pmid">30443714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Dringen</surname><given-names>R</given-names></name><name><surname>Pawlowski</surname><given-names>PG</given-names></name><name><surname>Hirrlinger</surname><given-names>J</given-names></name></person-group><article-title>Peroxide detoxification by brain cells</article-title><source>J Neurosci Res</source><year>2005</year><volume>79</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">15573410</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Dringen R, Pawlowski PG, Hirrlinger J (2005) Peroxide detoxification by brain cells. J Neurosci Res 79:157&#x02013;165<pub-id pub-id-type="pmid">15573410</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Dringen</surname><given-names>R</given-names></name><name><surname>Brandmann</surname><given-names>M</given-names></name><name><surname>Hohnholt</surname><given-names>MC</given-names></name><name><surname>Blumrich</surname><given-names>E-M</given-names></name></person-group><article-title>Glutathione-dependent detoxification processes in astrocytes</article-title><source>Neurochem Res</source><year>2015</year><volume>40</volume><fpage>2570</fpage><lpage>2582</lpage><pub-id pub-id-type="pmid">25428182</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Dringen R, Brandmann M, Hohnholt MC, Blumrich E-M (2015) Glutathione-dependent detoxification processes in astrocytes. Neurochem Res 40:2570&#x02013;2582<pub-id pub-id-type="pmid">25428182</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>McBean</surname><given-names>GJ</given-names></name></person-group><article-title>Cysteine, glutathione, and thiol redox balance in astrocytes</article-title><source>Antioxidants</source><year>2017</year><volume>6</volume><fpage>62</fpage><pub-id pub-id-type="pmid">28771170</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">McBean GJ (2017) Cysteine, glutathione, and thiol redox balance in astrocytes. Antioxidants 6:62<pub-id pub-id-type="pmid">28771170</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Couto</surname><given-names>N</given-names></name><name><surname>Wood</surname><given-names>J</given-names></name><name><surname>Barber</surname><given-names>J</given-names></name></person-group><article-title>The role of glutathione reductase and related enzymes on cellular redox homoeostasis network</article-title><source>Free Radic Biol Med</source><year>2016</year><volume>95</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">26923386</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Couto N, Wood J, Barber J (2016) The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radic Biol Med 95:27&#x02013;42<pub-id pub-id-type="pmid">26923386</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>ZB</given-names></name><name><surname>Zou</surname><given-names>XP</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Feng</surname><given-names>QL</given-names></name><name><surname>Zheng</surname><given-names>SC</given-names></name></person-group><article-title>Detoxification of insecticides, allechemicals and heavy metals by glutathione S-transferase SlGSTE1 in the gut of Spodoptera litura</article-title><source>Insect Sci</source><year>2015</year><volume>22</volume><fpage>503</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">24863567</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Xu ZB, Zou XP, Zhang N, Feng QL, Zheng SC (2015) Detoxification of insecticides, allechemicals and heavy metals by glutathione S-transferase SlGSTE1 in the gut of Spodoptera litura. Insect Sci 22:503&#x02013;511<pub-id pub-id-type="pmid">24863567</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>RR</given-names></name><name><surname>Reindl</surname><given-names>KM</given-names></name></person-group><article-title>Glutathione S-transferases in cancer</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><fpage>701</fpage><pub-id pub-id-type="pmid">33946704</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Singh RR, Reindl KM (2021) Glutathione S-transferases in cancer. Antioxidants 10:701<pub-id pub-id-type="pmid">33946704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Minich</surname><given-names>T</given-names></name><name><surname>Riemer</surname><given-names>J</given-names></name><name><surname>Schulz</surname><given-names>JB</given-names></name><name><surname>Wielinga</surname><given-names>P</given-names></name><name><surname>Wijnholds</surname><given-names>J</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes</article-title><source>J Neurochem</source><year>2006</year><volume>97</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">16539673</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Minich T, Riemer J, Schulz JB, Wielinga P, Wijnholds J, Dringen R (2006) The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. J Neurochem 97:373&#x02013;384<pub-id pub-id-type="pmid">16539673</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirrlinger</surname><given-names>J</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Multidrug resistance protein 1-mediated export of glutathione and glutathione disulfide from brain astrocytes</article-title><source>Methods Enzymol</source><year>2005</year><volume>400</volume><fpage>395</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">16399362</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Hirrlinger J, Dringen R (2005) Multidrug resistance protein 1-mediated export of glutathione and glutathione disulfide from brain astrocytes. Methods Enzymol 400:395&#x02013;409<pub-id pub-id-type="pmid">16399362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Waak</surname><given-names>J</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Formation and rapid export of the monochlorobimane&#x02013;glutathione conjugate in cultured rat astrocytes</article-title><source>Neurochem Res</source><year>2006</year><volume>31</volume><fpage>1409</fpage><lpage>1416</lpage><pub-id pub-id-type="pmid">17089195</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Waak J, Dringen R (2006) Formation and rapid export of the monochlorobimane&#x02013;glutathione conjugate in cultured rat astrocytes. Neurochem Res 31:1409&#x02013;1416<pub-id pub-id-type="pmid">17089195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirrlinger</surname><given-names>J</given-names></name><name><surname>Schulz</surname><given-names>JB</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells</article-title><source>J Neurosci Res</source><year>2002</year><volume>69</volume><fpage>318</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">12125073</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Hirrlinger J, Schulz JB, Dringen R (2002) Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J Neurosci Res 69:318&#x02013;326<pub-id pub-id-type="pmid">12125073</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Arend</surname><given-names>C</given-names></name><name><surname>Grothaus</surname><given-names>IL</given-names></name><name><surname>Waespy</surname><given-names>M</given-names></name><name><surname>Ciacchi</surname><given-names>LC</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Modulation of Multidrug resistance protein 1-mediated transport processes by the antiviral drug Ritonavir in cultured primary astrocytes</article-title><source>Neurochem Res</source><year>2024</year><volume>49</volume><fpage>66</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">37603214</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Arend C, Grothaus IL, Waespy M, Ciacchi LC, Dringen R (2024) Modulation of Multidrug resistance protein 1-mediated transport processes by the antiviral drug Ritonavir in cultured primary astrocytes. Neurochem Res 49:66&#x02013;84<pub-id pub-id-type="pmid">37603214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Cordes</surname><given-names>T</given-names></name><name><surname>Metallo</surname><given-names>CM</given-names></name></person-group><article-title>Itaconate alters succinate and Coenzyme a metabolism via inhibition of mitochondrial complex II and Methylmalonyl-CoA mutase</article-title><source>Metabolites</source><year>2021</year><volume>11</volume><fpage>117</fpage><pub-id pub-id-type="pmid">33670656</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Cordes T, Metallo CM (2021) Itaconate alters succinate and Coenzyme a metabolism via inhibition of mitochondrial complex II and Methylmalonyl-CoA mutase. Metabolites 11:117<pub-id pub-id-type="pmid">33670656</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Yang Y, Li Y, Yang W, Yang X, Luo M, Qin L, Zhu J (2024) Protecting effects of 4-octyl itaconate on neonatal hypoxic-ischemic encephalopathy via Nrf2 pathway in astrocytes. J Neuroinflamm 21:132</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Khadem</surname><given-names>MD</given-names></name><name><surname>Tabandeh</surname><given-names>MR</given-names></name><name><surname>Haschemi</surname><given-names>A</given-names></name><name><surname>Kheirollah</surname><given-names>A</given-names></name><name><surname>Shahriari</surname><given-names>A</given-names></name></person-group><article-title>Dimethyl itaconate reprograms neurotoxic to neuroprotective primary astrocytes through the regulation of NLRP3 inflammasome and NRF2/HO-1 pathways</article-title><source>Mol Cell Neurosci</source><year>2022</year><volume>122</volume><fpage>103758</fpage><pub-id pub-id-type="pmid">35868484</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Khadem MD, Tabandeh MR, Haschemi A, Kheirollah A, Shahriari A (2022) Dimethyl itaconate reprograms neurotoxic to neuroprotective primary astrocytes through the regulation of NLRP3 inflammasome and NRF2/HO-1 pathways. Mol Cell Neurosci 122:103758<pub-id pub-id-type="pmid">35868484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="book"><person-group person-group-type="author"><name><surname>Tulpule</surname><given-names>K</given-names></name><name><surname>Hohnholt</surname><given-names>M</given-names></name><name><surname>Hirrlinger</surname><given-names>J</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hirrlinger</surname><given-names>J</given-names></name><name><surname>Waagepetersen</surname><given-names>HS</given-names></name></person-group><article-title>Primary cultures of astrocytes and neurons as model systems to study the metabolism and metabolite export from brain cells</article-title><source>Neuromethods: Brain Energy Metabolism</source><year>2014</year><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><fpage>45</fpage><lpage>72</lpage></element-citation><mixed-citation id="mc-CR38" publication-type="book">Tulpule K, Hohnholt M, Hirrlinger J, Dringen R (2014) Primary cultures of astrocytes and neurons as model systems to study the metabolism and metabolite export from brain cells. In: Hirrlinger J, Waagepetersen HS (eds) Neuromethods: Brain Energy Metabolism. Springer, New York, pp 45&#x02013;72</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Petters</surname><given-names>C</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Comparison of primary and secondary rat astrocyte cultures regarding glucose and glutathione metabolism and the accumulation of iron oxide nanoparticles</article-title><source>Neurochem Res</source><year>2014</year><volume>39</volume><fpage>46</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">24190598</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Petters C, Dringen R (2014) Comparison of primary and secondary rat astrocyte cultures regarding glucose and glutathione metabolism and the accumulation of iron oxide nanoparticles. Neurochem Res 39:46&#x02013;58<pub-id pub-id-type="pmid">24190598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Dringen</surname><given-names>R</given-names></name><name><surname>Kranich</surname><given-names>O</given-names></name><name><surname>Hamprecht</surname><given-names>B</given-names></name></person-group><article-title>The &#x003b3;-glutamyl transpeptidase inhibitor acivicin preserves glutathione released by astroglial cells in culture</article-title><source>Neurochem Res</source><year>1997</year><volume>22</volume><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">9178957</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Dringen R, Kranich O, Hamprecht B (1997) The &#x003b3;-glutamyl transpeptidase inhibitor acivicin preserves glutathione released by astroglial cells in culture. Neurochem Res 22:727&#x02013;733<pub-id pub-id-type="pmid">9178957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Dringen</surname><given-names>R</given-names></name><name><surname>Hamprecht</surname><given-names>B</given-names></name></person-group><article-title>Glutathione content as an indicator for the presence of metabolic pathways of amino acids in astroglial cultures</article-title><source>J Neurochem</source><year>1996</year><volume>67</volume><fpage>1375</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">8858918</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Dringen R, Hamprecht B (1996) Glutathione content as an indicator for the presence of metabolic pathways of amino acids in astroglial cultures. J Neurochem 67:1375&#x02013;1382<pub-id pub-id-type="pmid">8858918</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>OH</given-names></name><name><surname>Rosebrough</surname><given-names>NJ</given-names></name><name><surname>Farr</surname><given-names>AL</given-names></name><name><surname>Randall</surname><given-names>RJ</given-names></name></person-group><article-title>Protein measurement with the Folin phenol reagent</article-title><source>J Biol Chem</source><year>1951</year><volume>193</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">14907713</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265&#x02013;275<pub-id pub-id-type="pmid">14907713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Watermann</surname><given-names>P</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>&#x003b2;-lapachone-mediated WST1 reduction as Indicator for the cytosolic redox metabolism of cultured primary astrocytes</article-title><source>Neurochem Res</source><year>2023</year><volume>48</volume><fpage>2148</fpage><lpage>2160</lpage><pub-id pub-id-type="pmid">36811754</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Watermann P, Dringen R (2023) &#x003b2;-lapachone-mediated WST1 reduction as Indicator for the cytosolic redox metabolism of cultured primary astrocytes. Neurochem Res 48:2148&#x02013;2160<pub-id pub-id-type="pmid">36811754</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Stapelfeldt</surname><given-names>K</given-names></name><name><surname>Ehrke</surname><given-names>E</given-names></name><name><surname>Steinmeier</surname><given-names>J</given-names></name><name><surname>Rastedt</surname><given-names>W</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Menadione-mediated WST1 reduction assay for the determination of metabolic activity of cultured neural cells</article-title><source>Anal Biochem</source><year>2017</year><volume>538</volume><fpage>42</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">28939007</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Stapelfeldt K, Ehrke E, Steinmeier J, Rastedt W, Dringen R (2017) Menadione-mediated WST1 reduction assay for the determination of metabolic activity of cultured neural cells. Anal Biochem 538:42&#x02013;52<pub-id pub-id-type="pmid">28939007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Steinmeier</surname><given-names>J</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Exposure of cultured astrocytes to Menadione Triggers Rapid Radical Formation, glutathione oxidation and Mrp1-Mediated export of glutathione disulfide</article-title><source>Neurochem Res</source><year>2019</year><volume>44</volume><fpage>1167</fpage><lpage>1181</lpage><pub-id pub-id-type="pmid">30806880</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Steinmeier J, Dringen R (2019) Exposure of cultured astrocytes to Menadione Triggers Rapid Radical Formation, glutathione oxidation and Mrp1-Mediated export of glutathione disulfide. Neurochem Res 44:1167&#x02013;1181<pub-id pub-id-type="pmid">30806880</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Watermann</surname><given-names>P</given-names></name><name><surname>Arend</surname><given-names>C</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>G6PDi-1 is a potent inhibitor of G6PDH and of Pentose phosphate pathway-dependent metabolic processes in cultured primary astrocytes</article-title><source>Neurochem Res</source><year>2023</year><volume>48</volume><fpage>3177</fpage><lpage>3189</lpage><pub-id pub-id-type="pmid">37394677</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Watermann P, Arend C, Dringen R (2023) G6PDi-1 is a potent inhibitor of G6PDH and of Pentose phosphate pathway-dependent metabolic processes in cultured primary astrocytes. Neurochem Res 48:3177&#x02013;3189<pub-id pub-id-type="pmid">37394677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Henderson J, Dayalan Naidu S, Dinkova-Kostova AT, Przyborski S, Stratton R, O&#x02032; Reilly S (2021) The cell-permeable derivative of the immunoregulatory metabolite itaconate, 4-octyl itaconate, is anti-fibrotic in systemic sclerosis. Cells 10:2053</mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Lampropoulou</surname><given-names>V</given-names></name><name><surname>Sergushichev</surname><given-names>A</given-names></name><name><surname>Bambouskova</surname><given-names>M</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Vincent</surname><given-names>EE</given-names></name><name><surname>Loginicheva</surname><given-names>E</given-names></name><name><surname>Cervantes-Barragan</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>SC-C</given-names></name><name><surname>Griss</surname><given-names>T</given-names></name></person-group><article-title>Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation</article-title><source>Cell Metabol</source><year>2016</year><volume>24</volume><fpage>158</fpage><lpage>166</lpage></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, Cervantes-Barragan L, Ma X, Huang SC-C, Griss T (2016) Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metabol 24:158&#x02013;166</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EL</given-names></name><name><surname>Ryan</surname><given-names>DG</given-names></name><name><surname>Prag</surname><given-names>HA</given-names></name><name><surname>Dikovskaya</surname><given-names>D</given-names></name><name><surname>Menon</surname><given-names>D</given-names></name><name><surname>Zaslona</surname><given-names>Z</given-names></name><name><surname>Jedrychowski</surname><given-names>MP</given-names></name><name><surname>Costa</surname><given-names>AS</given-names></name><name><surname>Higgins</surname><given-names>M</given-names></name><name><surname>Hams</surname><given-names>E</given-names></name></person-group><article-title>Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1</article-title><source>Nature</source><year>2018</year><volume>556</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">29590092</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, Jedrychowski MP, Costa AS, Higgins M, Hams E (2018) Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 556:113&#x02013;117<pub-id pub-id-type="pmid">29590092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>She</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Four-octyl itaconate activates Nrf2 cascade to protect osteoblasts from hydrogen peroxide-induced oxidative injury</article-title><source>Cell Death Dis</source><year>2020</year><volume>11</volume><fpage>772</fpage><pub-id pub-id-type="pmid">32943614</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zheng Y, Chen Z, She C, Lin Y, Hong Y, Shi L, Zhang Y, Cao P, Xu X (2020) Four-octyl itaconate activates Nrf2 cascade to protect osteoblasts from hydrogen peroxide-induced oxidative injury. Cell Death Dis 11:772<pub-id pub-id-type="pmid">32943614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W</given-names></name><name><surname>Henne</surname><given-names>A</given-names></name><name><surname>Lauterbach</surname><given-names>M</given-names></name><name><surname>Gei&#x000df;mar</surname><given-names>E</given-names></name><name><surname>Nikolka</surname><given-names>F</given-names></name><name><surname>Kho</surname><given-names>C</given-names></name><name><surname>Heinz</surname><given-names>A</given-names></name><name><surname>Dostert</surname><given-names>C</given-names></name><name><surname>Grusdat</surname><given-names>M</given-names></name><name><surname>Cordes</surname><given-names>T</given-names></name><name><surname>H&#x000e4;rm</surname><given-names>J</given-names></name><name><surname>Goldmann</surname><given-names>O</given-names></name><name><surname>Ewen</surname><given-names>A</given-names></name><name><surname>Verschueren</surname><given-names>C</given-names></name><name><surname>Blay-Cadanet</surname><given-names>J</given-names></name><name><surname>Geffers</surname><given-names>R</given-names></name><name><surname>Garritsen</surname><given-names>H</given-names></name><name><surname>Kneiling</surname><given-names>M</given-names></name><name><surname>Holm</surname><given-names>CK</given-names></name><name><surname>Metallo</surname><given-names>CM</given-names></name><name><surname>Medina</surname><given-names>E</given-names></name><name><surname>Abdullah</surname><given-names>Z</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Brenner</surname><given-names>D</given-names></name><name><surname>Hiller</surname><given-names>K</given-names></name></person-group><article-title>Mesaconate is synthesized from itaconate and exerts immunomodulatory effects in macrophages</article-title><source>Nat Metabolism</source><year>2022</year><volume>4</volume><fpage>524</fpage><lpage>533</lpage></element-citation><mixed-citation id="mc-CR51" publication-type="journal">He W, Henne A, Lauterbach M, Gei&#x000df;mar E, Nikolka F, Kho C, Heinz A, Dostert C, Grusdat M, Cordes T, H&#x000e4;rm J, Goldmann O, Ewen A, Verschueren C, Blay-Cadanet J, Geffers R, Garritsen H, Kneiling M, Holm CK, Metallo CM, Medina E, Abdullah Z, Latz E, Brenner D, Hiller K (2022) Mesaconate is synthesized from itaconate and exerts immunomodulatory effects in macrophages. Nat Metabolism 4:524&#x02013;533</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Mo</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name></person-group><article-title>The signaling pathways and therapeutic potential of itaconate to alleviate inflammation and oxidative stress in inflammatory diseases</article-title><source>Redox Biol</source><year>2022</year><volume>58</volume><fpage>102553</fpage><pub-id pub-id-type="pmid">36459716</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Shi X, Zhou H, Wei J, Mo W, Li Q, Lv X (2022) The signaling pathways and therapeutic potential of itaconate to alleviate inflammation and oxidative stress in inflammatory diseases. Redox Biol 58:102553<pub-id pub-id-type="pmid">36459716</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>MJ</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Loughran</surname><given-names>PA</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name></person-group><article-title>Immune-Responsive Gene 1/Itaconate activates nuclear factor erythroid 2&#x02013;Related factor 2 in hepatocytes to protect against Liver Ischemia&#x02013;Reperfusion Injury</article-title><source>Hepatology</source><year>2020</year><volume>72</volume><fpage>1394</fpage><lpage>1411</lpage><pub-id pub-id-type="pmid">31997373</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Yi Z, Deng M, Scott MJ, Fu G, Loughran PA, Lei Z, Li S, Sun P, Yang C, Li W, Xu H, Huang F, Billiar TR (2020) Immune-Responsive Gene 1/Itaconate activates nuclear factor erythroid 2&#x02013;Related factor 2 in hepatocytes to protect against Liver Ischemia&#x02013;Reperfusion Injury. Hepatology 72:1394&#x02013;1411<pub-id pub-id-type="pmid">31997373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Bambouskova</surname><given-names>M</given-names></name><name><surname>Gorvel</surname><given-names>L</given-names></name><name><surname>Lampropoulou</surname><given-names>V</given-names></name><name><surname>Sergushichev</surname><given-names>A</given-names></name><name><surname>Loginicheva</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Korenfeld</surname><given-names>D</given-names></name><name><surname>Mathyer</surname><given-names>ME</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>L-H</given-names></name><name><surname>Duncan</surname><given-names>D</given-names></name><name><surname>Bregman</surname><given-names>H</given-names></name><name><surname>Keskin</surname><given-names>A</given-names></name><name><surname>Santeford</surname><given-names>A</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name><name><surname>Sehgal</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>B</given-names></name><name><surname>Amarasinghe</surname><given-names>GK</given-names></name><name><surname>Soares</surname><given-names>MP</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Hai</surname><given-names>T</given-names></name><name><surname>de Strong</surname><given-names>G</given-names></name><name><surname>Auclair</surname><given-names>C</given-names></name><name><surname>Roddy</surname><given-names>K</given-names></name><name><surname>Biller</surname><given-names>TP</given-names></name><name><surname>Jovanovic</surname><given-names>SA</given-names></name><name><surname>Klechevsky</surname><given-names>M</given-names></name><name><surname>Stewart</surname><given-names>E</given-names></name><name><surname>Randolph</surname><given-names>KM</given-names></name><name><surname>Artyomov</surname><given-names>GJ</given-names></name></person-group><article-title>Electrophilic properties of itaconate and derivatives regulate the I&#x003ba;B&#x003b6;&#x02013;ATF3 inflammatory axis</article-title><source>Nature</source><year>2018</year><volume>556</volume><fpage>501</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">29670287</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Bambouskova M, Gorvel L, Lampropoulou V, Sergushichev A, Loginicheva E, Johnson K, Korenfeld D, Mathyer ME, Kim H, Huang L-H, Duncan D, Bregman H, Keskin A, Santeford A, Apte RS, Sehgal R, Johnson B, Amarasinghe GK, Soares MP, Satoh T, Akira S, Hai T, de Strong G, Auclair C, Roddy K, Biller TP, Jovanovic SA, Klechevsky M, Stewart E, Randolph KM, Artyomov GJ MN (2018) Electrophilic properties of itaconate and derivatives regulate the I&#x003ba;B&#x003b6;&#x02013;ATF3 inflammatory axis. Nature 556:501&#x02013;504<pub-id pub-id-type="pmid">29670287</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Loppi</surname><given-names>SH</given-names></name><name><surname>Tavera-Garcia</surname><given-names>MA</given-names></name><name><surname>Becktel</surname><given-names>DA</given-names></name><name><surname>Maiyo</surname><given-names>BK</given-names></name><name><surname>Johnson</surname><given-names>KE</given-names></name><name><surname>Nguyen</surname><given-names>T-VV</given-names></name><name><surname>Schnellmann</surname><given-names>RG</given-names></name><name><surname>Doyle</surname><given-names>KP</given-names></name></person-group><article-title>Increased fatty acid metabolism and decreased glycolysis are hallmarks of metabolic reprogramming within microglia in degenerating white matter during recovery from experimental stroke</article-title><source>J Cereb Blood Flow Metabolism</source><year>2023</year><volume>43</volume><fpage>1099</fpage><lpage>1114</lpage></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Loppi SH, Tavera-Garcia MA, Becktel DA, Maiyo BK, Johnson KE, Nguyen T-VV, Schnellmann RG, Doyle KP (2023) Increased fatty acid metabolism and decreased glycolysis are hallmarks of metabolic reprogramming within microglia in degenerating white matter during recovery from experimental stroke. J Cereb Blood Flow Metabolism 43:1099&#x02013;1114</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>L-L</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><article-title>Itaconate in host inflammation and defense</article-title><source>Trends Endocrinol Metabolism</source><year>2024</year><volume>35</volume><fpage>586</fpage><lpage>606</lpage></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Ye D, Wang P, Chen L-L, Guan K-L, Xiong Y (2024) Itaconate in host inflammation and defense. Trends Endocrinol Metabolism 35:586&#x02013;606</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>ElAzzouny</surname><given-names>M</given-names></name><name><surname>Tom</surname><given-names>CT</given-names></name><name><surname>Evans</surname><given-names>CR</given-names></name><name><surname>Olson</surname><given-names>LL</given-names></name><name><surname>Tanga</surname><given-names>MJ</given-names></name><name><surname>Gallagher</surname><given-names>KA</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Burant</surname><given-names>CF</given-names></name></person-group><article-title>Dimethyl itaconate is not metabolized into itaconate intracellularly</article-title><source>J Biol Chem</source><year>2017</year><volume>292</volume><fpage>4766</fpage><lpage>4769</lpage><pub-id pub-id-type="pmid">28188288</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">ElAzzouny M, Tom CT, Evans CR, Olson LL, Tanga MJ, Gallagher KA, Martin BR, Burant CF (2017) Dimethyl itaconate is not metabolized into itaconate intracellularly. J Biol Chem 292:4766&#x02013;4769<pub-id pub-id-type="pmid">28188288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Cordes</surname><given-names>T</given-names></name><name><surname>Lucas</surname><given-names>A</given-names></name><name><surname>Divakaruni</surname><given-names>AS</given-names></name><name><surname>Murphy</surname><given-names>AN</given-names></name><name><surname>Cabrales</surname><given-names>P</given-names></name><name><surname>Metallo</surname><given-names>CM</given-names></name></person-group><article-title>Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury</article-title><source>Mol Metabolism</source><year>2020</year><volume>32</volume><fpage>122</fpage><lpage>135</lpage></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Cordes T, Lucas A, Divakaruni AS, Murphy AN, Cabrales P, Metallo CM (2020) Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury. Mol Metabolism 32:122&#x02013;135</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Denker</surname><given-names>N</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Modulation of pyruvate export and extracellular pyruvate concentration in primary astrocyte cultures</article-title><source>Neurochem Res</source><year>2024</year><volume>49</volume><fpage>1331</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">38376749</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Denker N, Dringen R (2024) Modulation of pyruvate export and extracellular pyruvate concentration in primary astrocyte cultures. Neurochem Res 49:1331&#x02013;1346<pub-id pub-id-type="pmid">38376749</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Hohnholt</surname><given-names>MC</given-names></name><name><surname>Blumrich</surname><given-names>E-M</given-names></name><name><surname>Waagepetersen</surname><given-names>HS</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>The antidiabetic drug metformin decreases mitochondrial respiration and tricarboxylic acid cycle activity in cultured primary rat astrocytes</article-title><source>J Neurosci Res</source><year>2017</year><volume>95</volume><fpage>2307</fpage><lpage>2320</lpage><pub-id pub-id-type="pmid">28316081</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Hohnholt MC, Blumrich E-M, Waagepetersen HS, Dringen R (2017) The antidiabetic drug metformin decreases mitochondrial respiration and tricarboxylic acid cycle activity in cultured primary rat astrocytes. J Neurosci Res 95:2307&#x02013;2320<pub-id pub-id-type="pmid">28316081</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Cordes</surname><given-names>T</given-names></name><name><surname>Wallace</surname><given-names>M</given-names></name><name><surname>Michelucci</surname><given-names>A</given-names></name><name><surname>Divakaruni</surname><given-names>AS</given-names></name><name><surname>Sapcariu</surname><given-names>SC</given-names></name><name><surname>Sousa</surname><given-names>C</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Cabrales</surname><given-names>P</given-names></name><name><surname>Murphy</surname><given-names>AN</given-names></name><name><surname>Hiller</surname><given-names>K</given-names></name><name><surname>Metallo</surname><given-names>CM</given-names></name></person-group><article-title>Immunoresponsive Gene 1 and Itaconate Inhibit Succinate dehydrogenase to modulate intracellular succinate Levels*</article-title><source>J Biol Chem</source><year>2016</year><volume>291</volume><fpage>14274</fpage><lpage>14284</lpage><pub-id pub-id-type="pmid">27189937</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Cordes T, Wallace M, Michelucci A, Divakaruni AS, Sapcariu SC, Sousa C, Koseki H, Cabrales P, Murphy AN, Hiller K, Metallo CM (2016) Immunoresponsive Gene 1 and Itaconate Inhibit Succinate dehydrogenase to modulate intracellular succinate Levels*. J Biol Chem 291:14274&#x02013;14284<pub-id pub-id-type="pmid">27189937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Suhail</surname><given-names>H</given-names></name><name><surname>Nematullah</surname><given-names>M</given-names></name><name><surname>Rashid</surname><given-names>F</given-names></name><name><surname>Sajad</surname><given-names>M</given-names></name><name><surname>Fatma</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Zahoor</surname><given-names>I</given-names></name><name><surname>Cheung</surname><given-names>WL</given-names></name><name><surname>Tiwari</surname><given-names>N</given-names></name><name><surname>Ayasolla</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Hoda</surname><given-names>N</given-names></name><name><surname>Rattan</surname><given-names>R</given-names></name><name><surname>Giri</surname><given-names>S</given-names></name></person-group><article-title>An early glycolysis burst in microglia regulates mitochondrial dysfunction in oligodendrocytes under neuroinflammation</article-title><source>Iscience</source><year>2023</year><volume>26</volume><fpage>107921</fpage><pub-id pub-id-type="pmid">37841597</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Suhail H, Nematullah M, Rashid F, Sajad M, Fatma M, Singh J, Zahoor I, Cheung WL, Tiwari N, Ayasolla K, Kumar A, Hoda N, Rattan R, Giri S (2023) An early glycolysis burst in microglia regulates mitochondrial dysfunction in oligodendrocytes under neuroinflammation. Iscience 26:107921<pub-id pub-id-type="pmid">37841597</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>S-T</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>D-Q</given-names></name><name><surname>Fu</surname><given-names>X-W</given-names></name><name><surname>Wang</surname><given-names>J-S</given-names></name><name><surname>Kong</surname><given-names>L-Y</given-names></name></person-group><article-title>4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>5091</fpage><pub-id pub-id-type="pmid">31704924</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Liao S-T, Han C, Xu D-Q, Fu X-W, Wang J-S, Kong L-Y (2019) 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects. Nat Commun 10:5091<pub-id pub-id-type="pmid">31704924</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>R</given-names></name></person-group><article-title>4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>159</volume><fpage>114301</fpage><pub-id pub-id-type="pmid">36706634</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Yang W, Wang Y, Huang Y, Yu J, Wang T, Li C, Yang L, Zhang P, Shi L, Yin Y, Tao K, Li R (2023) 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer. Biomed Pharmacother 159:114301<pub-id pub-id-type="pmid">36706634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Differential effects of iodoacetamide and iodoacetate on glycolysis and glutathione metabolism of cultured astrocytes</article-title><source>Front Neuroenergetics</source><year>2009</year><volume>1</volume><fpage>463</fpage></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Schmidt M, Dringen R (2009) Differential effects of iodoacetamide and iodoacetate on glycolysis and glutathione metabolism of cultured astrocytes. Front Neuroenergetics 1:463</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>MM</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione</article-title><source>Neurochem Int</source><year>2010</year><volume>57</volume><fpage>460</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">20096739</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Schmidt MM, Dringen R (2010) Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem Int 57:460&#x02013;467<pub-id pub-id-type="pmid">20096739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>TJ</given-names></name><name><surname>Ak</surname><given-names>M</given-names></name><name><surname>Mrowietz</surname><given-names>U</given-names></name></person-group><article-title>Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine&#x02014;preparation of S-substituted thiosuccinic acid esters</article-title><source>Bioorg Med Chem</source><year>2007</year><volume>15</volume><fpage>333</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">17049250</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Schmidt TJ, Ak M, Mrowietz U (2007) Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine&#x02014;preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem 15:333&#x02013;342<pub-id pub-id-type="pmid">17049250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Fry&#x0010d;&#x000e1;k</surname><given-names>P</given-names></name><name><surname>Zdr&#x000e1;hal</surname><given-names>Z</given-names></name><name><surname>Ulrichov&#x000e1;</surname><given-names>J</given-names></name><name><surname>Wiegrebe</surname><given-names>W</given-names></name><name><surname>Lemr</surname><given-names>K</given-names></name></person-group><article-title>Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides</article-title><source>J Mass Spectrom</source><year>2005</year><volume>40</volume><fpage>1309</fpage><lpage>1318</lpage><pub-id pub-id-type="pmid">16177962</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Fry&#x0010d;&#x000e1;k P, Zdr&#x000e1;hal Z, Ulrichov&#x000e1; J, Wiegrebe W, Lemr K (2005) Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides. J Mass Spectrom 40:1309&#x02013;1318<pub-id pub-id-type="pmid">16177962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Atkins</surname><given-names>W</given-names></name></person-group><article-title>The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases</article-title><source>Cell Mol Life Sci CMLS</source><year>2005</year><volume>62</volume><fpage>1221</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">15798895</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Mahajan S, Atkins W (2005) The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases. Cell Mol Life Sci CMLS 62:1221&#x02013;1233<pub-id pub-id-type="pmid">15798895</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Boyland</surname><given-names>E</given-names></name><name><surname>Chasseaud</surname><given-names>L</given-names></name></person-group><article-title>Enzyme-catalysed conjugations of glutathione with unsaturated compounds</article-title><source>Biochem J</source><year>1967</year><volume>104</volume><fpage>95</fpage><pub-id pub-id-type="pmid">6035529</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Boyland E, Chasseaud L (1967) Enzyme-catalysed conjugations of glutathione with unsaturated compounds. Biochem J 104:95<pub-id pub-id-type="pmid">6035529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Tulpule</surname><given-names>K</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>Formaldehyde stimulates Mrp1-mediated glutathione deprivation of cultured astrocytes</article-title><source>J Neurochem</source><year>2011</year><volume>116</volume><fpage>626</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">21166805</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Tulpule K, Dringen R (2011) Formaldehyde stimulates Mrp1-mediated glutathione deprivation of cultured astrocytes. J Neurochem 116:626&#x02013;635<pub-id pub-id-type="pmid">21166805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Brandmann</surname><given-names>M</given-names></name><name><surname>Tulpule</surname><given-names>K</given-names></name><name><surname>Schmidt</surname><given-names>MM</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes</article-title><source>J Neurochem</source><year>2012</year><volume>120</volume><fpage>78</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22017299</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Brandmann M, Tulpule K, Schmidt MM, Dringen R (2012) The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. J Neurochem 120:78&#x02013;92<pub-id pub-id-type="pmid">22017299</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Arend</surname><given-names>C</given-names></name><name><surname>Brandmann</surname><given-names>M</given-names></name><name><surname>Dringen</surname><given-names>R</given-names></name></person-group><article-title>The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes</article-title><source>Neurochem Res</source><year>2013</year><volume>38</volume><fpage>732</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">23341120</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Arend C, Brandmann M, Dringen R (2013) The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes. Neurochem Res 38:732&#x02013;741<pub-id pub-id-type="pmid">23341120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>ZL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Structural basis of substrate recognition by the multidrug resistance protein MRP1</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>1075</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">28238471</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Johnson ZL, Chen J (2017) Structural basis of substrate recognition by the multidrug resistance protein MRP1. Cell 168:1075&#x02013;1085<pub-id pub-id-type="pmid">28238471</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Human Protein Atlas proteinatlas.org (2024) <ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/ENSG00000165621-OXGR1/tissue/cerebral+cortex">https://www.proteinatlas.org/ENSG00000165621-OXGR1/tissue/cerebral+cortex</ext-link></mixed-citation></ref></ref-list></back></article>